Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Gap Up to $5.40

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) shares gapped up prior to trading on Wednesday . The stock had previously closed at $5.40, but opened at $5.76. Amneal Pharmaceuticals shares last traded at $5.79, with a volume of 637,860 shares trading hands.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. The Goldman Sachs Group increased their price target on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a report on Monday, March 4th. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. Piper Sandler increased their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Finally, Barclays increased their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, January 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average target price of $7.31.

Amneal Pharmaceuticals Trading Down 2.5 %

The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.94 and a current ratio of 1.63. The business has a fifty day simple moving average of $5.72 and a 200 day simple moving average of $5.18. The company has a market cap of $1.81 billion, a P/E ratio of -19.03 and a beta of 1.33.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Friday, March 1st. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. The company had revenue of $616.98 million for the quarter, compared to the consensus estimate of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. Analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current fiscal year.

Institutional Trading of Amneal Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Gladius Capital Management LP bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $39,000. Sherbrooke Park Advisers LLC bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $54,000. Trexquant Investment LP bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $65,000. TCG Advisory Services LLC bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $91,000. Finally, Aigen Investment Management LP bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $118,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.